PT-141 (Bremelanotide) for Adults 65 and Older: School, Activity, and Daily Life Considerations

What the Studies Actually Show

The two RECONNECT phase 3 trials enrolled 1,267 women and followed treatment for 24 weeks. Participants were premenopausal, with acquired, generalized hypoactive sexual desire disorder. Bremelanotide improved sexual-desire scores and reduced distress compared with placebo. The number of satisfying sexual events did not differ significantly between groups. [2]

This distinction matters when reading claims about results. Improved desire scores are a measured outcome; they are not proof that everyone will have more sexual activity. The trial publication is the appropriate source for those outcomes, rather than an unrelated phase 2 paper.

What Changes at Age 65?

The prescribing information reports a participant age range of 19 to 56 and states that safety and effectiveness have not been established in geriatric patients. Vyleesi's indication is acquired, generalized HSDD in premenopausal women. There is no label-supported geriatric dose or age-based exercise schedule. [1, sections 1, 8.5 and 14]

Age alone cannot fill this research gap. General observations about aging do not demonstrate how much longer bremelanotide lasts in a particular older adult or predict their response.

Blood Pressure and Activity Timing

The label describes average maximum increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after dosing and usually returning to baseline within 12 hours. Twelve hours is the return-to-baseline window, not the peak. [1, section 5.1]

The contraindications are uncontrolled hypertension and known cardiovascular disease. The label does not establish a universal 12-hour ban on walking, swimming, classes or exercise. An activity plan cannot be inferred from the blood-pressure curve alone. [1, sections 4 and 5.1]

The Naltrexone Interaction Runs in the Other Direction

Bremelanotide can reduce systemic exposure to oral naltrexone. Naltrexone does not inactivate the bremelanotide injection. The label advises avoiding Vyleesi with oral naltrexone products used for alcohol or opioid addiction because reduced exposure could undermine that treatment. [1, section 7.2]

This is a reason to identify the exact product and purpose of treatment. A medication list is more useful than assuming every medicine in a broad category behaves identically.

Nausea and Practical Daily Life

Nausea was reported by 40.0% of bremelanotide-treated participants versus 1.3% with placebo in RECONNECT. Those figures describe the studied population; they do not establish a higher rate in people over 65. [2]

Planning around symptoms means identifying the actual activity: a class, a commute, exercise or time with a partner. These activities have different demands. A universal timetable would give a false impression of precision where the trial evidence does not supply one.

Reading Longer-Term Results

The RECONNECT extension followed participants who chose to continue after the core trials. Its open-label design and selected population help describe longer-term experience, but do not establish effectiveness in adults aged 65 and older. [3]

For more information about the medicine and the studies, see the PT-141 guide. Keep the formulation, study population and measured outcome together when comparing claims.

References

1. Cosette Pharmaceuticals. Vyleesi (bremelanotide) prescribing information, revised March 2024; DailyMed listing updated November 2025. Sections 1, 4, 5.1, 7.2, 8.5 and 14. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/

3. Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology. 2019;134(5):909-917. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/